⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HURA News
TuHURA Biosciences, Inc. Common Stock
Form 8-K
sec.gov
HURA
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
prnewswire.com
HURA
Advancements in Novel Immunotherapeutics in The Oncology Battle Ready to Announce with Confidence?
newsfilecorp.com
AEMD
HURA
AZN
ELTX
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
prnewswire.com
HURA
KTRA
JNJ
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
prnewswire.com
HURA
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
prnewswire.com
HURA
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
prnewswire.com
HURA
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
prnewswire.com
HURA
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
prnewswire.com
HURA
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
prnewswire.com
HURA